Skip to content

Curemark Secures $20 Million in Equity Financing

13 July, 2015

RYE, New York, July 13, 2015 — Curemark LLC announced today the closing of $20 million in equity financing from the Frist Family. William and Jennifer Frist are directors in numerous healthcare corporations, foundations and enterprises including Healthcare Corporation of America (HCA). Mrs. Frist joins Curemark’s Board of Directors and will bring her business, patient advocacy and philanthropic experience to Curemark.

“This investment positions the company for growth and expansion,” states Dr. Joan Fallon, Curemark founder and CEO. “We are extremely grateful to Jennifer and Billy for their investment in Curemark and their support of our mission to get CM-AT to children with autism.”

Curemark recently announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism. Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of the digestive enzyme chymotrypsin. The Company is currently submitting its rolling New Drug Application for CM-AT for autism under the FDA’s Fast Track designation.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit

Safe-Harbor Statements

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.